Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in North Miami, Florida. Sunnyside North Miami, located at 505 NE 125^th St., is Cresco Labs’ first location in Miami-Dade County, 15^th store in Florida and 49^th dispensary nationwide. The Company’s upcoming Lady Lake store will be its 50^th in the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220207005284/en/

Sunnyside North Miami is Cresco Labs’ first store in Miami-Dade County, 15th location in Florida and 49th dispensary nationwide. (Photo: Business Wire)

“We’re thrilled to welcome North Miami patients to Sunnyside’s retail experience for the first time,” said Charlie Bachtell, CEO and Co-founder of Cresco Labs. “One of our priorities this year is to expand access to Cresco Labs portfolio of high-quality and diverse cannabis products and to that end we will be opening new dispensaries across Florida all year.”

Sunnyside North Miami is a highly accessible retail location situated on a busy retail corridor and a few blocks away from the heavily trafficked I-95 Expressway and State Road 909. The medical cannabis dispensary will serve patients in Miami-Dade County with simple online ordering and convenient next-day delivery service.

Patients of the new store will have access one of the largest selections of cannabis products and accessories, including One Plant’s top selling, premium, hand-trimmed flower and solventless live rosin concentrates, as well as vape cartridges, pre-rolls, tinctures, lighters, rolling papers and more. Regular store hours are Monday through Saturday, 10 a.m. to 8 p.m., and Sunday, 10 a.m. to 5 p.m.

In addition to the North Miami opening, Cresco Labs serves patients through its Sunnyside dispensaries in Avon Park, Boynton Beach, Orlando (Fern Park), Jacksonville Beach, Ocala, Port St. Lucie, St. Petersburg, Bonita Springs, Fort Lauderdale, Oakland Park, Tallahassee, Pensacola, Sarasota and Clearwater.

For more information about Sunnyside and to place online orders, visit www.sunnyside.shop.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005284/en/